This Texas Medical Center startup is digitizing employee expense management within health care. Photo courtesy of TMC

The Texas Medical Center announced a partnership with San Francisco-based Bond Financial Technologies Inc this month on a platform that will bring an embedded financial solution into the realm of health care expenses.

According to a statement from the companies, inefficiencies make up about 35 percent of the $5 trillion annual health care expenditure in the U.S.

To find a solution, TMC Innovation launched its own fintech company, Tanaflow, which aims to digitize health care expense management through applying machine-based learning. Bond Financial launched Bond Treasury in tandem to facilitate the innovation.

Together the products will first aim to tackle the often paper-based and cumbersome task of employee expense reimbursements, which accounts for an estimated $300 million a year at TMC, according to the statement.

“TMC’s Tanaflow will use Bond Treasury to embed financial services into our software applications to save time and money so we can refocus on serving the more than 10 million patients we see annually,” Odero Otieno, founder in residence at TMC and CEO of Tanaflow, says in a statement. “Over time, we expect to expand into other non-clinical tasks and transactions, such as payment acquiring, treasury management, and credit. Bond has the technology platform, talent, and vision to be our long-term partner and we are incredibly excited to partner on this new journey.”

The Tanaflow technology will be integrated across TMC's 61 institutions and 21 hospitals.

This will be Bond Financial's first foray into the health care industry. The company, founded in 2019, aims to create, launch and scale embedded financial experiences across industries at an enterprise level through its API platform. Investors include the likes of Goldman Sachs and Mastercard.

"We’re seeing tremendous interest from enterprise businesses that want to embed purpose-built financial products into their software applications, and are excited to partner with impactful organizations such as TMC to bring more efficiencies into the healthcare vertical,” Roy Ng, co-founder and CEO of Bond, adds in a statement.

The TMC is also currently underway on its 250,000-square-foot, $186 million TMC3 Collaborative Building, which will house research initiatives and foster collaboration among academic health care institutions and industry partners. Slated to open in the fall of 2023, it's also designed to support strategic initiatives and investment from life science-focused firms and national venture and equity and partners.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”